Beta-Cell function: Although the plasma insulin response to the development of insulin resistance typically is increased during the natural history of T2DM , this does not mean that the beta cell is functioning normally. To the contrary, studies have demonstrated that the onset of beta-cell failure occurs much earlier and is more severe than previously appreciated.

New mobile app from Medtronic, Sugar.IQ™, applies AI technology from IBM Watson Health to help people with diabetes make more informed decisions.

With over 6 million possible combinations, it is difficult to come up with the best treatment for each patient. The phase III DURATION-8 trial may help you to decide.

DEPICT-2 study of more than 800 people worldwide indicates positive results without added risk of severe hypoglycemia, but slight increase in DKA events.

One-year results of North American inTandem1 study show decreased HbA1c levels and lower risk of severe hypoglycemia.

The FDA approved the 90-day version of the implantable CGM Sensor.

For those who use insulin, accuracy is one of the most important things to consider when using a CGM.

“Simple,” “Accurate,” and “Effective” were the words ADA presenters used to describe Dexcom G6, a new continuous glucose monitor (CGM) system.

A dual-hormone, artificial pancreas delivering rapid insulin and the drug pramlintide improved glucose management and reduced glucose variability in adults with type 1 compared to an insulin-only, first-generation artificial pancreas.

Do you recommend a CGM for all your patients who are not achieving their target blood glucose and who are on insulin? Follow the link to respond.